Expected Moves

Alfresa's Q2 fiscal 2027 earnings report, revealing whether the severe 49.8% YoY net income contraction from the prior quarter has stabilized.

Market assimilation of the preliminary National Health Insurance (NHI) drug price cuts by the Japanese government and Alfresa's margin defense strategy.

Q3 results capturing peak winter pharmaceutical distribution volumes and early impacts from operational cost-cutting.

Release of fiscal year-end results, FY28 guidance, and potential updates to share buybacks or dividend policies in response to TSE guidelines.

First quarter results for the new fiscal year, providing the initial read on how the April NHI price cuts actually impacted net margins.